Initial Analysis of OSTA-1 Ocean Color Experiment Imagery

Ocean images were obtained at three widely separated locations on the earth as part of NASA's ocean color experiment. Digital computer enhancement and band-ratioing techniques were applied to radiometrically corrected spectral data to emphasize patterns of chlorophyll distribution and, in one case, of bottom topography. The chlorophyll pattern in the Yellow Sea between China and Korea was evident in a scene produced from shuttle orbit 24. The effects of the discharge from the Yangtze and other rivers were also observed. Two scenes from orbits 30 and 32 revealed the movement of patches of plankton in the Gulf of Cádiz. Geometric corrections of these images permitted ocean current velocities in the vicinity to be deduced. The variability in water depth over the Grand Bahama Bank was estimated by using the blue-green channel of the instrument. The very clear water conditions in the area caused bottom-reflected sunlight to produce a sensor signal that was inversely related to the depth of the water.     

鹧鸪属23种鸟类的鸣声结构、鸣叫行为及基于鸣声的分组(英文)

本文描述了鹧鸪属(Pternistis spp.)23种鸟类的鸣叫特点,比较了占区/求偶鸣叫在种间的差异,并依据鸣叫(主要为占区/求偶鸣叫)特征,对这23种鹧鸪进行了分组。共分析了非洲所有23种鹧鸪的22个种的218段录音、约300句鸣叫,另有一种鹧鸪的鸣叫分析源于文献。结果表明,每种鹧鸪可发出7–11种鸣叫,这些鸣叫可分为3大类:1)占区/求偶鸣叫;2)警戒叫声、雏鸟和亚成鸟索群叫声、觅食叫声等维持群体关系叫声;3)雌雄两性间以及雌鸟与幼鸟间联络鸣叫。Hall(1963)将鹧鸪分为5个单系类群。本文将鹧鸪的鸣叫分为8个组,其中的5个组与Hall(1963)划分的单系类群基本一致。不同种类间占区/求偶鸣叫的差异虽然减少了同域分布的鹧鸪种间的杂交,但由于鹧鸪的遗传距离较小,种间杂交仍不可避免。本研究还基于鸣声确认了哈氏鹧鸪(P.hartlaubi)仍属于鹧鸪属鸟类,尽管其叫声与其它鹧鸪叫声有很大的差异。     

Pyloric stenosis caused by hypertrophic gastritis in three dogs

Hypertrophic gastritis of the pyloric antrum is described in an 11-year-old female poodle, a 14-year-old male Maltese terrier and a 13-year-old male mongrel. The dogs suffered from chronic vomiting. Gastroscopic examination revealed mucosal proliferations in dogs 1 and 3. Radiographic examination showed signs of pyloric obstruction in all three dogs. Contrast studies demonstrated thickenings in the region of the pylorus in dogs 1 and 2. Laparotomy was done in all three dogs: in dog 1 a gastro-duodenostomy was performed and in dogs 2 and 3 the circularly thickened mucosa was resected. The mucosa of all three dogs showed hypertrophic gastritis, chiefly due to foveolar hyperplasia, and round cell infiltration, especially in the superficial layers. Herniation of mucosal glands through the muscularis mucosae was found in dog 1. Dogs 1 and 2 recovered well and vomiting ceased. Dog 3 continued to vomit because of a pyloric stenosis, mainly due to muscular hypertrophy.     

Radiology of deciduous teeth resorption and definitive teeth eruption in the dog

The formation of the crown of definitive teeth, the development of the definitive roots with the accompanying resorption of the deciduous roots, and the eruption of the definitive teeth, were individually analysed in 18 Dachshunds.
Weekly radiographs were made from all dogs between the sixth and twentieth weeks of life, using techniques applied in the human dental clinic. From this data a table has been drawn representing the radiological evolution of the entire dentition in young Dachshunds.     

A comparative study of the pharmacokinetics of intravenous and oral trimethoprim/sulfadiazine formulations in the horse

The biopharmaceutical properties of four fuced trimethoprim/sulfonamide combinations were investigated in the horse. Eight fasted horses were dosed at 1 week intervals in a sequentially designed study with one intravenous (i.v.) and three oral trimethoprim/sulfadiazine (TMP/SDZ) formulations (1, 2 and 3) administered at a dose of 5 mg/kg trimethoprim (TMP) and 25 mg/kg sulfadiazine (SDZ). Plasma concentrations of each compound were monitored for 48 h. Pharmacokinetic parameters (volume of distribution, bioavailability and total body clearance) for TMP and SDZ were calculated and compared. After oral administration plasma concentrations of TMP and SDZ increased rapidly. With all three paste formulations, TMP peak plasma concentrations were attained within 2 h. SDZ mean peak plasma concentrations were reached at 2.59 ± 0.48 h for a commercial paste (l), and at 1.84 ± 0.66 h and 1.95 ± 0.61 h for the two self-made formulations (2 and 3). Mean peak plasma TMP concentrations (± SD) were 1.72 ± 0.36 μg/ml, 1.42 ± 0.37 μg/ml and 1.31 ± 0.36 μ g/d, and mean peak plasma SDZ concentrations 12.11 ± 4.5 5 μg/ml, 12.72 ± 3.47 μg/ml and 15.45 ± 4.74 μg/ml for preparations 1, 2 and 3. The bioavailability of TMP was 67.0 ± 20.3%, 57.7 ±21.6% and 60.9 f 18.9% and of SDZ 57.6 ± 14.8%, 59.3 ± 19.5% and 65.9 ± 5.8% for SDZ for 1, 2 and 3, respectively. Following i.v. administration TMP/SDZ plasma concentration ratios approached the optimal 1:20 ratio (It 10%) for about 5 h, but following the oral administrations this ratio was only achieved for a very short time-span. No adverse effects were seen following i.v. and oral administration. In considering the pharmacokinetic data in combination with in vitro antibacterial sensitivity data, it is concluded that treatment at a dose of 5 mg/kg TMP and 25 mg/kg SDZ with a dosing interval of 12 h can be regarded as therapeutically effective for susceptible bacteria (MIC₉₀ 0.25/4.75) for all three oral formulations. It is concluded that neither the formulation nor the addition of different excipients result in significantly different bioavailabilities.     

Trimethoprim/sulfonamide combinations in the horse: a review

Van Duijkeren, E., Vulto, A.G., van Miert, A.S.J.P.A.M. Trimethoprim/sulfonamide combinations in the horse: a review. J. vet. Pharmacol. Therap. 17 , 64–73. The indications for use, side-effects, and pharmacokinetic parameters of trimethoprim, sulfonamides and their combinations in the horse are reviewed. Trimethoprim/sulfonamide (TMPS) combinations are used for the treatment of various diseases caused by gram-positive and gram-negative bacteria, including infections of the respiratory tract, urogenital tract, alimentary tract, skin Joints and wounds- TMPS combinations can be administered orally, since absorption from the gastrointestinal tract is relatively good. However, peak serum concentrations can vary significantly between individual horses. Feed intake affects serum concentrations after oral administration. Concentrations of non-bound trimethoprim (TMP) and sulfadiazine (SDZ) in synovial fluid and peritoneal fluid are equal to serum concentrations after intravenous (i.v.) administration, and high concentrations are found in urine. Concentrations of TMP and sulfamethoxazole (SMX) in cerebrospinal fluid after i.v. administration exceed the minimum inhibitory concentration for common equine pathogens. The volume of distribution is 1.5-2.71/kg for TMP and 0.3-0.7 1/kg for various sulfonamides. The plasma half-life of TMP is 1.9-4.3 h, whereas the plasma half-lives of the different sulfonamides vary between 2.7 and 14.0 h. About 50% of total TMP is bound to plasma proteins. The binding of sulfadox-ine to plasma proteins depends on total plasma concentration and varies between 14% and 72%. The binding of other sulfonamides to plasma proteins may range from 33% for sulfaphenazole (SPZ) to 93% for sulfadimethoxine (SDM). Sulfonamides are metabolized by acetylation of the para-amino (N₄) group and by hydroxylation of the methyl group and the pyrimidine ring. The metabolic pathways of TMP in the horse are not fully known. Bacterial resistance to TMPS combinations is still relatively low. The sensitivity of different micro-organisms may vary with the relative activity of the sulfonamide used in the combination. The advised oral and i.v. dose rate is 15–30 mg/kg (in a 1:5 TMP/S ratio) with a dose interval of 12 h. The acute toxicity of TMPS is low, but there have been several reports of death after i.v. administration, probably due to vagal stimulation and subsequent bradycardia and vasodilatation caused by the pharmaceutical formulation (excipients, solvents) used. Future research should concentrate on establishing the optimum pyrimidine/sulfonamide combination and its dosing regimen for antimicrobial therapy in horses.